Login to Your Account

Tweak to Supernus ADHD trial sends shares lower

By Michael Fitzhugh
Staff Writer

Tuesday, September 19, 2017

Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with ADHD that it was evaluating in twin phase III studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription